Evidence map›Paper›PMID 41221627›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Dysregulation of CircZNF79(5) Modulates YBX1 Stability and Selective Autophagy to Drive Hepatocellular Carcinoma Progression.

Xueqiang Guo, Lingling Xi, Yukun Liu, Wenbao Lv, Tianzi Li, Andong Ju, Zhenlin Fan, Yaping Shen, Zhuang Qian, Weiyun Wang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. CircPRKCA Promotes NSCLC Progression via miR-200b-3p/FRMD6/SNAI2 Axis.International journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Xueqiang GuoThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.ORCID https://orcid.org/0000-0003-2318-8678
Lingling XiThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Yukun LiuThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Wenbao LvThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Tianzi LiThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Andong JuAbdominal Surgical Oncology, Xinxiang Central Hospital, Institute of the Fourth Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Zhenlin FanThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Yaping ShenThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Zhuang QianClinical Medical Center of Tissue Engineering and Regeneration, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Weiyun WangThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Zhuo LiangClinical Medical Center of Tissue Engineering and Regeneration, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Wenjuan SongThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Kaiwen ChangThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Shuangping MaThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Junhe ZhangThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Tao HanThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Kun YouThe First Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Cunshuan XuCollege of Life Science, Henan Normal University, Xinxiang, 453003, P. R. China.
Lei WangClinical Medical Center of Tissue Engineering and Regeneration, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Weisheng GuoClinical Medical Center of Tissue Engineering and Regeneration, Xinxiang Medical University, Xinxiang, 453003, P. R. China.ORCID https://orcid.org/0000-0002-8064-357X
Wenjie RenThe First Affiliated Hospital of Xinxiang Medical University, Institutes of Health Central Plain, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Xinxiang Key Laboratory of Molecular Oncology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy with limited therapeutic options. Circular RNAs (circRNAs) have emerged as critical regulators in various cancers, including HCC, but their roles in HCC progression remain largely unexplored. Here, the role of circZNF79(5) in HCC progression and its underlying mechanisms is investigated. CircZNF79(5) expression in HCC tissues, cell lines and the serum exosomes is analyzed using qRT-PCR and FISH, and evaluated its effects on cell proliferation, migration, invasion and apoptosis using CCK8, colony formation, EdU, Transwell and Flow cytometry. CircZNF79(5)'s is verified to be upregulated in HCC, and found that it can promote HCC cells proliferation, migration and invasion, while inhibiting the apoptosis. Mechanistically, circZNF79(5) is found to stabilizes the oncogenic protein YBX1 by recruiting BRCC36, a K63 chain deubiquitinating enzyme, thereby preventing YBX1 from p62-mediated selective autophagic degradation via the AMPK/mTOR signaling pathway. In vivo studies using subcutaneous and orthotopic tumor models confirmed that circZNF79(5) knockdown reduced tumor growth and YBX1 expression. The findings reveal a novel mechanism by which circZNF79(5) promotes HCC progression through YBX1 stabilization and selective autophagy regulation, highlighting the circZNF79(5)-YBX1-BRCC36 axis as a potential therapeutic target for HCC.

Indexed as

AutophagyCarcinoma, HepatocellularLiver NeoplasmsRNA, CircularY-Box-Binding Protein 1AnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeRNA, CircularY-Box-Binding Protein 1YBX1 protein, humanBRCC36, circZNF79(5)HCC, p62selective autophagyYBX1

Identifiers

PMID41221627
PMCPMC12866679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.